Cheapest Way to Get GLP-1 Medications Online in 2026

Last updated: October 1, 2026 · Written by Ash Heleka

The lowest advertised telehealth prices we track start around $129-$149 per month for products marketed as compounded semaglutide and $149-$199 for compounded tirzepatide, before checking dose changes and extra fees. Those products are not FDA-approved or generic equivalents. Eligible patients may pay less for an FDA-approved product through insurance, a manufacturer card, the Medicare GLP-1 Bridge, or a self-pay program. I compared pricing records across 94 providers and checked manufacturer programs on October 1, 2026.

Below is a full breakdown of advertised prices, eligibility rules, and the tradeoffs among insurance, manufacturer offers, and telehealth programs. If you want to understand how compounded and brand-name GLP-1s differ, we cover that in a separate guide.

TL;DR: The Cheapest Options Right Now

If you want the short answer, here it is:

• Lowest compounded-semaglutide records: Found Health ($129/mo) and Yucca Health ($146/mo on a six-month plan); verify current all-in checkout terms
• Lowest compounded-tirzepatide promotions: tracked offers start around $163-$249/mo depending on provider and commitment; verify the pharmacy, dose pricing, and patient-specific medical need
• Brand-name tirzepatide self-pay (Zepbound): Lilly’s current offer starts at $299/mo for 2.5 mg, with eligibility and refill terms
• Brand-name semaglutide self-pay (Wegovy): NovoCare currently starts at $149/mo for certain tablet doses and $199/mo for eligible starter injections
• Potential commercial-insurance minimum: Manufacturer savings cards advertise brand-name costs as low as $25/mo for eligible patients, subject to caps and terms (see our insurance coverage guide)

The rest of this guide explains the tradeoffs, red flags, and details behind each option.

Brand-Name vs. Compounded GLP-1s: What You Need to Know

The difference between brand-name and compounded GLP-1 products is not just price. Wegovy and Zepbound are FDA-approved products made under reviewed manufacturing controls. Products marketed as compounded semaglutide or tirzepatide are not FDA-approved, and the FDA does not verify their identity, safety, effectiveness, quality, or therapeutic equivalence. In 2026 the agency also warned that some products used semaglutide salt forms or carried false pharmacy information. A lower advertised price therefore comes with materially different regulatory and quality assurance.

Brand-Name GLP-1 Medications

These are the FDA-approved drugs made by the pharmaceutical companies that developed them:

• Ozempic (semaglutide, by Novo Nordisk), approved for type 2 diabetes
• Wegovy (semaglutide, by Novo Nordisk), approved for weight management
• Mounjaro (tirzepatide, by Eli Lilly), approved for type 2 diabetes
• Zepbound (tirzepatide, by Eli Lilly), approved for weight management

These products went through FDA review for specific indications, formulations, and dosing schedules. Depending on the product, the approved presentation may be a tablet, single-dose pen, multi-dose KwikPen, or vial. For the listed injectable products, wholesale acquisition costs remain far above the manufacturer self-pay offers discussed below.

Compounded GLP-1 Medications

Compounded drugs are prepared for identified patients by state-licensed pharmacies under Section 503A or by registered outsourcing facilities under Section 503B when all applicable legal conditions are met. Registration or a state license does not mean the compounded product is FDA-approved.

Key facts about compounded GLP-1s:

• They are not FDA-approved, and FDA does not verify that a marketed product contains the represented ingredient or is equivalent to a brand-name drug
• Advertised telehealth prices are often lower than injectable list prices, but the all-in cost must be compared with insurance and current manufacturer self-pay offers
• Lawful compounding depends on the pharmacy, prescription, ingredient source, patient-specific need, and the restrictions that apply under 503A or 503B
• The broad shortage-era exemption for making essentially copies narrowed after FDA resolved the tirzepatide and semaglutide shortages

The critical caveat: In February 2026 the FDA announced enforcement against misleading mass marketing of non-FDA-approved GLP-1 products, and in April it proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list. More on this below.

Price Comparison: GLP-1 Telehealth Providers

The telehealth records in our database advertise prices from $129 to $499 per month as of August 2026, while current manufacturer self-pay offers start at $149 for certain Wegovy tablet doses and $299 for Zepbound. The spread is wide because some prices cover only medication while others bundle visits, coaching, and shipping. The advertised price and all-in monthly cost can differ once membership fees or dose increases are added. Always verify the current checkout price and commitment on the provider’s website.

A few things to note about this table:

1. Prices change frequently. Always check the provider’s current site.
2. Watch for separate fees. Some providers advertise a medication price but charge a separate membership, consultation, or lab fee. Ro currently charges $74-$149 per month after the first month depending on membership commitment, in addition to medication.
3. Dose may matter. Some providers charge more as the dose increases, while others use flat or prepaid pricing. Check the full schedule.
4. Upfront billing. Some providers (Hims/Hers in particular) offer their best monthly rate only when you pay for 6-12 months upfront.

Insurance vs. Cash Pay: Which Is Actually Cheaper?

The cheaper route depends on the plan’s allowed price, deductible, copay or coinsurance, indication, and eligibility for a manufacturer offer. With qualifying commercial coverage, some brand-name savings programs advertise costs as low as $25 per month. Without useful coverage, compare the exact all-in cost of a manufacturer self-pay route with any telehealth program rather than assuming either insurance or compounding wins.

When Insurance Makes Sense

If you have commercial insurance (employer-provided or marketplace) that covers GLP-1 medications for weight management or type 2 diabetes, and you pair it with a manufacturer savings card, you could pay as little as $25 per month for brand-name Wegovy, Zepbound, Mounjaro, or Ozempic.

For a patient who actually reaches the $25 minimum, that is below the compounded-program prices in this comparison. The amount is not guaranteed: plan coverage, savings caps, prior authorization, step therapy, and specialty-tier cost sharing can change the final price.

Insurance is worth pursuing if:

• Your plan explicitly covers Wegovy, Zepbound, or other GLP-1s for weight management
• You have a diabetes diagnosis (coverage for Ozempic/Mounjaro for T2D is more common)
• Your employer offers a plan with obesity-medication benefits
• You qualify for manufacturer savings cards (more on these below)

When Cash Pay / Compounded Is Cheaper

For many people, insurance either does not cover GLP-1s for weight loss at all, or the out-of-pocket cost after insurance is still $300-$500+/month due to high specialty copays or coinsurance.

Cash pay is worth comparing if:

• Your insurance does not cover GLP-1 medications for weight management
• Your plan denied a prior authorization after you and the prescriber completed the available requirements or appeal
• Your specialty copay or coinsurance is higher than the all-in cash price you qualify for
• You are on a high-deductible plan and have not met your deductible

In those cases, compare the final checkout amount, formulation, pharmacy, clinical services, refill rules, and cancellation terms. A lower compounded-program price is not a substitute for determining whether compounding is lawful and medically appropriate for the identified patient.

My personal experience: I initially tried to go through insurance for Mounjaro. The prior authorization took three weeks, got denied, and the appeal took another month. By the time I had an answer (still denied for weight loss), I could have been on medication for two months through a cash-pay provider. Time has a cost too.

Manufacturer Savings Programs

Manufacturer programs can reduce brand-name costs to as little as $25 for eligible commercially insured patients. Self-pay routes are separate: Zepbound starts at $299 and NovoCare currently starts certain Wegovy tablet doses at $149 and eligible starter injections at $199. Copay cards cannot be combined with Medicare or Medicaid, but some self-pay offers can be used entirely outside government benefits; those payments do not count toward the plan’s deductible or out-of-pocket limit.

Eli Lilly Savings Card (Mounjaro & Zepbound)

Mounjaro Savings Card (for type 2 diabetes):

• Pay as little as $25 per month with eligible commercial insurance
• Maximum savings, fill limits, and expiration are governed by Lilly’s current program terms
• Not available for Medicare, Medicaid, or other government insurance

Zepbound self-pay offer (for an approved use):

• Vial or single-patient-use KwikPen availability depends on the route and prescription
• As low as $299/month for 2.5 mg
• As low as $399/month for 5 mg
• As low as $449/month for 7.5 mg, 10 mg, 12.5 mg, and 15 mg
• Eligibility, savings caps, and other current program terms apply
• A refill within 45 days is required to continue the KwikPen purchase offer

For someone prescribed Zepbound who lacks useful coverage, compare this offer with the plan-specific out-of-pocket price. The advertised amount is not guaranteed for every patient, dose, pharmacy route, or fill.

Novo Nordisk (Wegovy & Ozempic)

Wegovy Savings Card:

• Pay as little as $25 per month with eligible commercial insurance
• Maximum savings of $100 per 1-month fill
• The copay benefit cannot be combined with government insurance; a separate self-pay purchase may still be available outside those benefits

NovoCare Pharmacy Direct Pricing:

• Wegovy tablets start at $149/month for the 1.5mg dose. The 4mg dose’s $149 introductory rate ended August 31, 2026, and is now $199/month. The 9mg and 25mg doses run $299/month
• New patients can get the first two fills of the 0.25 mg and 0.5 mg injection doses for $199/month through December 31, 2026
• Standard Wegovy injection self-pay pricing is $349/month after the introductory fills
• Wegovy HD is $399/month under the current self-pay offer
• Offers are time-limited, so check NovoCare before each fill

Novo Nordisk Patient Assistance Program (PAP):

• For qualifying low-income patients without insurance coverage
• Product eligibility and program terms change; check Novo Nordisk’s current PAP medication list rather than assuming Wegovy or Ozempic is included

The Compounding Pharmacy Situation: What You Need to Know

The FDA has resolved the national shortage designations for tirzepatide and semaglutide. That removed the broad shortage-based flexibility that many pharmacies used to make essentially copies of the approved drugs. Compounding may still be appropriate when an identified patient’s medical need cannot be met by an available FDA-approved drug, but it is not a general route to a cheaper copy.

How Compounding Became a Thing

When an approved drug is on FDA’s shortage list, some restrictions on making an essentially copy may not apply if the compounder meets all other federal and state requirements. Those shortage provisions no longer broadly apply to semaglutide or tirzepatide.

The Shortage Is Over. What Now?

As of August 2026, this means:

• The legal basis for mass-producing compounded semaglutide and tirzepatide has narrowed significantly
• The FDA has signaled it will prioritize enforcement against certain mass-marketed compounded GLP-1 products
• Patient-specific compounding may remain permissible in limited circumstances when an available FDA-approved product cannot meet the identified patient’s medical need and all legal conditions are satisfied
• FDA has warned about fraudulent labels, dosing errors, salt forms, and adverse-event reports involving compounded products

What This Means for You

In practical terms, as of August 2026:

1. Compounded GLP-1s are still available from many providers, but the legal ground is shifting.
2. Prices may change. If compounding becomes more restricted, the cheap semaglutide and tirzepatide options could disappear or get more expensive.
3. Brand-name direct prices are lower than list price. Zepbound self-pay starts at $299 and eligible higher doses can cost $449 through the Journey Program. NovoCare’s standard Wegovy injection self-pay price is $349 after any introductory offer.
4. Enforcement is active. FDA has warned telehealth marketers and compounders and proposed tighter limits on GLP-1 bulk substances.

What to do: Prefer an FDA-approved product when it is available and medically appropriate, which is also FDA’s recommendation. If a prescriber recommends a compounded product for a patient-specific need, verify the dispensing pharmacy and ask why the approved product cannot meet that need. Read the FDA’s current warning on unapproved GLP-1 products before paying.

How to Actually Order GLP-1 Medications Online

An online route generally involves a health history, review by a clinician licensed for your location, a prescription if appropriate, dispensing through a pharmacy, and follow-up. Timing, required visits or labs, eligibility criteria, and shipping differ by provider and product. Every legitimate route requires a valid prescription from a licensed clinician.

Step 1: Choose a Provider and Sign Up

Pick a telehealth provider from the comparison table above (or from our full provider comparison). You will create an account and fill out a health questionnaire. This typically asks about:

• Your height, weight, and BMI
• Medical history (diabetes, heart conditions, thyroid issues)
• Current medications
• Weight loss goals
• Whether you have tried other weight loss methods

For weight management, many programs use criteria tied to the prescribed product’s FDA-approved indication, but the clinician must assess the full indication, contraindications, age, comorbidities, and individual circumstances.

Step 2: Telehealth Consultation

A licensed prescriber (doctor, NP, or PA) reviews your information. Depending on the provider, this happens as:

• Asynchronous review: The prescriber reviews your questionnaire and messages you
• Video visit: A scheduled telehealth appointment where you speak with the prescriber live
• Phone call: Less common, but some providers offer this

The prescriber determines if you are a candidate for a GLP-1 medication and writes a prescription if appropriate. Some providers require lab work (bloodwork) before prescribing. Others do not.

Step 3: Prescription and Pharmacy

Once prescribed, the medication is either:

• Shipped from a partner pharmacy directly to you (compounded providers)
• Filled at a retail pharmacy you choose (some brand-name prescriptions)
• Shipped via the manufacturer’s direct program (LillyDirect, NovoCare Pharmacy)

Shipping method and timing depend on the product, pharmacy, destination, and labeled storage requirements. Confirm those details before paying.

Step 4: Start Your Medication

Several GLP-1 products are weekly subcutaneous injections, while Wegovy also has a daily tablet formulation. Starting doses, escalation intervals, missed-dose instructions, and maintenance doses are product-specific. Follow the FDA-approved label and the prescriber’s directions for the exact product.

Approved injection devices differ: some are single-dose pens, some are multi-dose pens, and some presentations are vials. Compounded medications may use a vial with a concentration and syringe units that differ by pharmacy. Use only the instructions for the dispensed product; do not convert a dose from another presentation. If you are starting tirzepatide, check our Mounjaro dosage guide and confirm the prescription instructions.

Step 5: Ongoing Refills and Check-ins

Refill cadence and check-ins vary. Before enrolling, confirm how the provider handles side effects, dose changes, urgent questions, renewals, pauses, and cancellation.

Red Flags: What to Avoid

A prescription, a properly licensed prescriber, and a verifiable dispensing pharmacy are minimum checks, not a guarantee of product quality or clinical care. FDA has warned about counterfeit Ozempic, products sold as “research grade,” fraudulent pharmacy labels, salt forms, and dosing errors. An unusually low price is one warning sign, but there is no official $129-$199 legitimacy floor.

Overseas Pharmacies and “Research Peptides”

Do not buy semaglutide or tirzepatide from:

• Online sellers that bypass prescription or lawful-import requirements. Do not rely on a website’s country, logo, or lab claim as proof of identity or quality.
• Peptide research supply companies that sell “research-grade” semaglutide labeled “not for human consumption.” These products are not manufactured under pharmaceutical-grade conditions. They are intended for laboratory research, not injection into your body.
• Unverifiable social-media sellers offering prescription drugs without a valid prescription, licensed dispenser, and traceable supply chain.

Warning Signs of an Illegitimate Provider

Watch out for:

• No telehealth consultation required. Any legitimate provider must have a licensed prescriber evaluate you before dispensing a prescription medication.
• No verifiable U.S. dispensing facility. Check the pharmacy’s state license. If a seller claims a 503B outsourcing facility is involved, also verify that facility on FDA’s registration list; neither status means FDA approved the compounded drug.
• Prices that seem too good to be true. If someone is offering semaglutide for $50/month, question where it is coming from.
• No ongoing medical supervision. A responsible provider monitors you with regular check-ins, not just a one-time prescription.
• Pressure to prepay without clear terms. Multi-month plans can be legitimate, but avoid sellers that do not disclose cancellation, refund, dose-change, pharmacy, and ongoing-clinical-review terms before payment.

How to Verify a Compounding Pharmacy

If you want to verify that a compounding pharmacy is legitimate:

1. Check the state board of pharmacy where the pharmacy is located. They should have an active license.
2. Verify claimed accreditation. PCAB accreditation is voluntary and does not make a product FDA-approved.
3. Verify the category. A 503A pharmacy is state-regulated and compounds for identified patients under prescriptions; a 503B outsourcing facility registers with FDA and is subject to current good manufacturing practice requirements and FDA inspection.
4. Ask for batch-specific quality information. Ask what potency, sterility, and endotoxin testing applies to the dispensed lot and who performed it. A test claim alone does not establish equivalence to an approved product.

The Bottom Line: My Recommendation

The lowest cost depends on insurance, indication, dose, and program eligibility. Commercial copay offers can reach $25, the Medicare GLP-1 Bridge is $50 for eligible beneficiaries, NovoCare currently starts certain Wegovy tablets at $149, Wegovy starter injections at $199, and Zepbound self-pay at $299. Compounded programs may advertise lower prices but are not FDA-approved or generic equivalents.

If you have commercial insurance that covers GLP-1s: Check the plan formulary and the relevant manufacturer terms. Eligible patients may pay as little as $25, but the advertised minimum is not guaranteed and benefit caps can leave a larger balance.

If you do not have insurance coverage and want brand-name: Compare the Zepbound self-pay offer, which starts at $299 under current terms, with NovoCare’s Wegovy offers, which start at $149 for certain tablet doses and $199 for eligible starter injections.

If a clinician identifies a patient-specific need for a compounded product: Our provider records advertise compounded semaglutide programs in the $129-$199/month range. Verify the all-in price, pharmacy, product details, and why an available approved product cannot meet that need.

If you want tirzepatide (dual GIP/GLP-1) at the lowest cost: Our provider records advertise compounded tirzepatide starting around $179-$279/month. Lilly’s current Zepbound self-pay offer starts at $299 for the 2.5 mg starting dose; compare eligibility, presentation, follow-up, and total cost.

Regardless of which route you choose: Verify the dispensing pharmacy’s state license or 503B registration, understand that neither status makes the product FDA-approved, and confirm that a licensed prescriber will provide follow-up. Do not buy injectable medication from an unverifiable source.

Frequently Asked Questions

Is compounded semaglutide the same as Ozempic or Wegovy?

No. Ozempic and Wegovy are FDA-approved semaglutide products with reviewed manufacturing controls. A product marketed as compounded semaglutide is not FDA-approved or a generic equivalent, and FDA does not verify its identity, quality, safety, effectiveness, or therapeutic equivalence. FDA has also warned that some marketed products use semaglutide salt forms or fraudulent pharmacy labels.

Can I get Ozempic online without a prescription?

No. Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are prescription medications. Any legitimate provider will require a telehealth consultation with a licensed prescriber before dispensing. If someone offers to sell you these medications without a prescription, that is a major red flag.

How much does Ozempic cost without insurance?

Brand-name Ozempic has a list price of $1,027.51 per 28-day supply as of August 2026. Eligible self-pay patients can obtain the 0.25mg, 0.5mg, or 1mg pen for $349 per month and the 2mg pen for $499 through NovoCare, subject to current terms. Wegovy is a different product with its own program.

Will compounded GLP-1s still be available in 2026?

As of August 2026, products marketed as compounded GLP-1s remain available, but FDA has resolved the semaglutide and tirzepatide shortages and is actively enforcing restrictions on mass-marketed copies and misleading claims. Patient-specific compounding may be lawful only when all applicable conditions are satisfied.

What is the difference between semaglutide and tirzepatide?

Semaglutide (Ozempic, Wegovy) is a GLP-1 receptor agonist. Tirzepatide (Mounjaro, Zepbound) is a dual GIP and GLP-1 receptor agonist, meaning it targets two hormones instead of one. In clinical trials, tirzepatide showed slightly greater average weight loss than semaglutide. Both are effective, and the best choice depends on your individual response and medical history.

Do I need a BMI of 30 to qualify?

Adult weight-management indications commonly use a BMI of 30 or higher, or 27 or higher with at least one weight-related condition, but the exact FDA indication and provider criteria depend on the product and patient. The prescriber must make the final determination.

How quickly do GLP-1 medications work?

Onset and weight-loss trajectory vary by product, dose escalation, adherence, health conditions, and individual response. Trial averages measured at fixed study endpoints do not predict what one person will lose or how quickly. Ask the prescriber what response and safety markers to monitor.

Can I switch from compounded to brand-name (or vice versa)?

A prescriber may recommend a change, but there is no approved dose-equivalence table between compounded products and FDA-approved brands. Product identity, concentration, dosing units, indication, and treatment gaps must be reviewed before any switch. Do not convert or reuse a prior dose on your own.

This article is for informational purposes only and does not constitute medical advice. Pricing information is approximate and based on publicly available data checked in October 2026. Actual costs and eligibility vary. Always consult with a qualified healthcare provider before starting any medication. ClearMetabolic may earn a commission through provider links on this page. See our full disclosure.

Related

Guides:

• Cheapest GLP-1 Online · Insurance Coverage · Side Effects
• Mounjaro Dosage Guide · Oral vs Injectable · Exercise and Muscle
• Compounded vs Brand-Name · Without Insurance
• Fat Loss vs Weight Loss · DEXA Scan Results · Mounjaro Plateau · Medicare Coverage · Wegovy Pill vs Injection

Provider Reviews: Ro · Hims · MEDVi · Found · Calibrate

Tools: GLP-1 Cost Estimator · Body Composition Calculator

Compare: All Providers · Best GLP-1 Programs · Cheapest Programs · Starter Deals · All Guides